Lexaria Bioscience Corp. (NASDAQ: LEXX) Grows Global Patent Portfolio to 41; Maintains Focus on GLP-1 Clinical Studies for 2024

  • Lexaria, a global innovator in drug delivery platforms, has added three new patents to its portfolio, bringing the total to 41
  • Two patents were awarded in the U.S., while the third was awarded in Japan, expiring in 2042 and 2041, respectively, if not extended
  • Lexaria’s management plans to maintain focus on GLP-1 studies for 2024

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, in the month of April 2024, added three new patents to its portfolio. This brings the total number of awarded patents globally to 41, a testament to the versatility of its patented DehydraTECH(TM) technology and its overall viability in the potential treatment of various ailments including, but not limited to, diabetes, weight loss and hypertension.

Two newly granted patents were awarded in the U.S. They fall under Lexaria’s patent family #24: Compositions and Methods for Treating Epilepsy. These two patents complement earlier research that discovered DehydraTECH-CBD was capable of mitigating epileptic seizures in animals, and was also absorbed into the bloodstream more effectively than the commercially available CBD-based anti-seizure medication, Epidiolex(R).

The third patent was granted in Japan under Lexaria’s patent family #18: Compositions and Methods for Enhanced Delivery of Antiviral Agents. This patent followed Lexaria’s demonstration of a 42%-204% improved delivery of antiviral drugs, as evidenced in numerous animal studies over the years. The first two patents will expire in 2042, while the last one will expire in 2041 if both are not extended.

These three additions bolster Lexaria’s intellectual property, which remains significant in supporting future business objectives. They are also integral in growing the company’s shareholder value, an avenue it seeks to pursue even further as time progresses. Even so, Lexaria is still committed to focusing on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year, having shown positive results in an 8-week clinical study in 2023. At the start, the company’s foray into GLP-1 studies was considered a “high-risk” program, according to the CEO, Chris Bunka. This mainly stemmed from the fact that this was a class of drugs considered “large molecules,” a class that Lexaria had never explored before, given its focus on “small molecules” (https://cnw.fm/ITon1).

Despite the challenges and concerns, Lexaria’s GLP-1 study was a huge success that aligned with the rising interest in GLP-1 drugs owing to their health benefits. As such, the company looks to concentrate on these studies, even as it grows its intellectual property globally.

“Our R&D plans for 2024 are very tightly focused and will be concentrated mainly on GLP-1 investigations. We are not at this time planning additional 2024 research in the antiviral nicotine, or PDE5 sectors. We have solid early-stage data in each of those areas that will allow us to build upon those at the right time,” noted Mr. Bunka.

GLP-1 studies will run alongside international patent applications. Upcoming patents are expected to cover swallowed capsules and dissolvable oral tablets. Lexaria’s management is confident in its current direction and maintains that 2024 will be the year the company’s hard work will prove itself. It is a testament to its commitment to creating shareholder value and asserting itself as a leader in its space.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CBDWire

CBDWire (“CBDW”) is a specialized communications platform with a focus on CBD related news and updates in the cannabidiol (“CBD”) sector. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, CBDW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, CBDW brings its clients unparalleled recognition and brand awareness.

CBDW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from CBDWire, text “CBDWire” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://www.CBDWire.com/Disclaimer

Denver, CO
303.498.7722 Office

CBDWire is powered by IBN


Select A Month

CBDWire Currently Accepts



Bitcoin Cash

Bitcoin Cash

Doge Coin






USD Coin

USD Coin

Contact us: 303.498.7722